Cargando…

Applying Desirability of Outcome Ranking End Points

Detalles Bibliográficos
Autores principales:	Dunne, Michael W, Aronin, Steven I, Das, Anita F, Gupta, Jayanti, Akinapelli, Karthik, Zelasky, Michael T, Puttagunta, Sailaja, Boucher, Helen W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320050/ https://www.ncbi.nlm.nih.gov/pubmed/36974506 http://dx.doi.org/10.1093/cid/ciad166

Ejemplares similares

Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections
por: Dunne, Michael W, et al.
Publicado: (2023)

Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial
por: Dunne, Michael W, et al.
Publicado: (2022)

Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial
por: Dunne, Michael W, et al.
Publicado: (2022)

2106. Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI)
por: Aronin, Steven I, et al.
Publicado: (2023)

LB-1. Efficacy and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women: Results from the SURE-1 Trial
por: Dunne, Michael W, et al.
Publicado: (2020)

Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure Infection
por: Rappo, Urania, et al.
Publicado: (2020)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
por: Dunne, Michael W., et al.
Publicado: (2016)

1393. A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Subjects Under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with Probenecid to Determine the Pharmacokinetics of Sulopenem
por: Dunne, Michael, et al.
Publicado: (2018)

1527. The Prevalence of Enterobacteriaceae (ENT) Resistant to All Major Classes of Oral Antibiotics from Outpatient Urine Cultures in the United States and Effect on Clinical Outcomes
por: Dunne, Michael, et al.
Publicado: (2018)

1363. Sulopenem Activity Against Enterobacteriaceae Isolates From Patients With Urinary Tract Infection or Intra-Abdominal Infection
por: Puttagunta, Sailaja, et al.
Publicado: (2018)

Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible Enterobacterales
por: Dunne, Michael W., et al.
Publicado: (2022)

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
por: Dunne, Michael W., et al.
Publicado: (2015)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
por: Dunne, Michael W, et al.
Publicado: (2015)

1724. Murine Efficacy Studies of Sulopenem Against Bacillus anthracis
por: Puttagunta, Sailaja, et al.
Publicado: (2022)

Sulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for Enterobacterales Isolates
por: Puttagunta, Sailaja, et al.
Publicado: (2023)

In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program
por: Maher, Joshua M, et al.
Publicado: (2023)

Ranking, selecting, and prioritising genes with desirability functions
por: Lazic, Stanley E.
Publicado: (2015)

What Sexual Behaviors Relate to Decreased Sexual Desire in Women? A Review and Proposal for End Points in Treatment Trials for Hypoactive Sexual Desire Disorder
por: Pyke, Robert, et al.
Publicado: (2016)

Current desires of conspecific observers affect cache-protection strategies in California scrub-jays and Eurasian jays
por: Ostojić, Ljerka, et al.
Publicado: (2017)

The Mouse Uterotrophic Assay: Other End Points
por: Newbold, RR
Publicado: (2001)

Surrogate end points and their role in clinical trial
por: Jaykaran,
Publicado: (2009)

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects
por: Scoble, Patrick J., et al.
Publicado: (2015)

Malarial Fevers. Geo. Ranking
por: Ranking, George
Publicado: (1893)

Surrogate end points and their role in clinical trials: Reply from authors
por: Kalikar, M.V., et al.
Publicado: (2009)

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion
por: Rappo, Urania, et al.
Publicado: (2019)

Inaccuracy of the log‐rank approximation in cancer data analysis
por: Rappoport, Nimrod, et al.
Publicado: (2019)

1232. Efficacy and Safety of Intravenous Sulopenem Followed by Oral Sulopenem etzadroxil/Probenecid Versus Intravenous Ertapenem Followed by Oral Ciprofloxacin or Amoxicillin-clavulanate in the Treatment of Complicated Urinary Tract Infections (cUTI): Results from the SURE-2 Trial
por: Dunne, Michael W, et al.
Publicado: (2020)

International ranking systems for universities and institutions: a critical appraisal
por: Ioannidis, John PA, et al.
Publicado: (2007)

2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

Porokeratosis and Lichen Planus: Co-Localisation or Isotopic Response or Koebner's Phenomenon?
por: Datta, Jayanti, et al.
Publicado: (2022)

A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection
por: Howard-Anderson, Jessica, et al.
Publicado: (2022)

COVID-19 Vaccination and Inflammatory Bowel Disease: Desired Antibody Responses, Future Directions, and a Note of Caution
por: Levine, Irving, et al.
Publicado: (2022)

Who should be responsible for the care of advanced chronic kidney disease? Do the guidelines point to the end of nephrology follow-up of advanced CKD or are they the starting point for a new approach?
por: Piccoli, Giorgina Barbara
Publicado: (2020)

Users’ guide to point‐of‐care ultrasonography
por: Tanael, Michael
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jjjfsks2hq0jvld15dqpm7rc5f